Prescriber's Letter, an evidence-based resource for medical professionals, provides clear recommendations on treatment of type 2 diabetes and analysis of recent warnings of increased heart attack risks associated with Avandia.
Stockton, CA (PRWEB) May 31, 2007 -- Prescribers and diabetes patients alike are wondering what to make of recent media reports of a New England Journal of Medicine study suggesting Avandia (rosiglitazone) increases heart attack risk by 43% in diabetes patients. Avandia, an oral agent for type 2 diabetes, accounted for more than 3 billion dollars in worldwide sales last year. Critics are jumping to liken these N Engl J Med study results to the early cardiovascular concerns seen with Vioxx that ultimately led to its removal from the market.
But analysts at Prescriber's Letter say that crunching the study's numbers reveals only part of the story. Since this report is a meta-analysis, it is merely a study of prior study results. In order to draw conclusions that can be applied by health professionals and patients, one has to consider this study along with earlier data and knowledge of a particular patient.
Prescriber's Letter helps prescribers and patients put this new study into perspective. Experts are concluding that, as with many other diabetes medications, Avandia's only definite benefit is lowering blood glucose to help control diabetes. This new study reinforces that Avandia does not provide any long-term cardiovascular benefit in diabetes patients. In fact, it's well known that both available drugs in the "glitazone" class, Avandia and Actos (pioglitazone), cause fluid retention and should be avoided in patients with moderate to severe heart failure.
Prescriber's Letter also addresses another question raised by this study. People want to know if the heart attack risk is a "class-effect" that will be observed with Actos. This study does not answer this question since it did not look at Actos. Another highly debated study suggests that Actos (pioglitazone) may actually reduce heart attacks and strokes. But the jury is still very much out on whether all the drugs in this glitazone class lead to cardiovascular problems.
Even more important for prescribers and patients, though, is how to make treatment decisions based on the results of the new Avandia study.
Prescriber's Letter experts say to follow the recommendations in its Stepwise Order of Treatments For Type 2 Diabetes. After diet and exercise, most patients should be started on metformin. If a glitazone drug is to be started, preference should be given to Actos over Avandia. But if a patient is already stable and doing well on Avandia the patient should not be switched to Actos at this time, based only on the results of this study.
Prescriber's Letter, an evidence-based subscription resource for prescribers, provides the facts about the quality and results of studies like this one, without any spin or sensationalism. A concise analysis of this study is available at www.prescribersletter.com/newsroom/avandia. In the article, the editors tell prescribers what they need to know to translate this study into practice. The editors also attach their Detail-Document that explores the facts that shaped the Letter's recommendations. This added resource also provides the Stepwise Order of Treatment guidelines and a handout to help doctors counsel patients on the risks of Avandia and Actos. Thousands of articles and Detail-Documents like this one are available at www.prescribersletter.com.
The editorial team at Prescriber's Letter has been publishing drug information recommendations since 1985 and carefully researches the most important topics and compiles the evidence into monthly Letters consisting of concise articles each linked to an in-depth Detail-Document. In order to remain completely unbiased, Prescriber's Letter does not accept any advertising and has no ties with any drug manufacturing company.
About Therapeutic Research
Therapeutic Research is a completely independent research and publishing organization that provides evidence-based information for physicians, pharmacists, and other medical professionals. Therapeutic Research publishes Prescriber's Letter, Pharmacist's Letter, PL Journal Club, Natural Medicines Comprehensive Database, Ident-A-Drug Reference, and a variety of continuing medical education courses including live courses. Therapeutic Research accepts no advertising and provides objective information for subscribers.
Contact
Julie McCloud
Therapeutic Research Center
Therapeutic Research Faculty
3120 West March Lane
Stockton, CA 95219
Phone: 209-472-2240
Fax: 209-472-2247
http://www.therapeuticresearch.com/newsroom
http://www.prescribersletter.com/newsroom
#.##
Press Contact: Julie McCloud
Company Name: Therapeutic Research Center
Phone: 209-472-2240
Website: www.prescribersletter.com
Victor Dyment, Healer/Scientist, is not what usually first comes to mind when one thinks of a health and wellness expert. He is muscular and academic in appearance, Russian born, and can pass on first glance as an athletic weight lifter or college professor. Appearances--like health--can be deceiving. Dyment is, in fact, the co-author of "A Journey Towards Health" and the founder and leading practitioner of a new branch of alternative medicine, known as Health Frequency. His approach to healing, in combination with the body's natural processes, brings relief to many patients where traditional treatment has failed--and is often a lifesaver.
(PRWEB) May 28, 2007 -- Victor Dyment, Healer/Scientist, is not what usually first comes to mind when one thinks of a health and wellness expert. He is muscular and academic in appearance, Russian born, and can pass on first glance as an athletic weight lifter or college professor. Appearances--like health--can be deceiving. Dyment is, in fact, the co-author of "A Journey Towards Health" and the founder and leading practitioner of a new branch of alternative medicine, known as Health Frequency. His approach to healing, in combination with the body's natural processes, brings relief to many patients where traditional treatment has failed--and is often a lifesaver.
"Health Frequency refers to a level of frequency in the stem cells produced by bone marrow," said Dyment. "There is only one frequency that is healthy, and it is affected by everyday materials including fabrics and incompatible dental materials previously used in dental work." When people wear or use them, the body reacts biochemically, causing numerous problems including an overall deterioration in health and wellness, sleep disorders, and even serious illness such as cancer and autoimmune diseases.
"Teeth are the most important access to health," adds Dyment. "Dental materials render the greatest influence on the state of health of the immune system, cardiovascular condition and high-grade work of cells in the body. A large percentage of discomfort and serious health problems are due to inappropriate dental materials. Mercury amalgams, composites, bonding cements, many metals, porcelains or other materials not compatible to Health Frequency negatively affect cellular structures and all functions in the body."
"Traditional medical and scientific research focuses on chemical solutions for treatment," he said. "I focus on the body's frequency," Dyment emphasizes.
Dyment has treated approximately one thousand patients ranging in symptoms from chronic migraines and severe back pain to autoimmune and kidney disorders. It is not uncommon for his patients to first be misdiagnosed by traditional physicians for years before learning of Health Frequency.
One such patient, Jane Parker who later became co-author with Dyment of the book "A Journey Towards Health" approached him about her scleroderma, an autoimmune disease characterized by the formation of scar tissue (fibrosis) in the skin and organs of the body. This condition leads to thickness and firmness of involved areas, and considerable pain. It is also characterized by short life expectancy.
"I was diagnosed with pain and numbness in my hands and arms," said Parker. "Doctors told me I had arthritis, then carpal tunnel syndrome, then Lupus, and finally, scleroderma. I simply did not accept the death sentence."
Dyment uses simple touch by placing his hand over the problem area to allow his frequency to enter the muscle, bones, and ultimately bone marrow of a patient. In effect, his healthy health frequency heals that of his patients.
"By the end of my first treatment, I felt a significant reduction in pain," explained Parker. "I felt better."
Under Dyment's care, Parker replaced clothes and improved her personal environment. Gone were bed sheets, couches, and mattresses that negatively affected frequency. Substituted in their place were linens and furniture made with the right material.
According to Dr.Mark D. Horowitz M.D., P.C, Parker was able to taper off Prednisone within six months and the scleroderma was completely reversed within three years.
In an effort to treat more patients, Dyment has been working to produce two products that reduce frequency pollution in the body. The first, a gold alloy in the form of a ring, causes healthy biochemical reactions in the body. The second, a dental alloy, is designed to replace mercury fillings and other incompatible materials previously used in dental work, a leading cause of frequency problems.
About Health Frequency:
To learn more about Health Frequency, visit www.healthfrequency.com.
#-##
Press Contact: FRED YAEGER
Company Name: Yaeger Public Relations
Phone: 914-423-7972
Website: www.healthfrequency.com
Alternative cancer treatment facility in Mesa AZ, An Oasis of Healing, launches AnOasisOfHealing.com. Thomas Lodi, MD, Homeopathic Physician and owner of An Oasis of Healing, explains the fundamental steps needed to take to naturally heal cancer.
Mesa, AZ (PRWEB) May 26, 2007 -- Thomas Lodi, MD, Homeopathic Physician and owner of An Oasis of Healing, Integrative Oncology Cancer Treatment facility in Mesa, Arizona, has just launched his new website AnOasisOfHealing.com, which provides options for alternative cancer treatment.
AnOasisofHealing.com provides you with information about the three fundamental aspects employed to treat cancer: (1) Teaching the patient to stop making cancer (2) Selectively targeting and destroying cancer without harming the person (3) Stimulating and enhancing the immune system.
Dr. Thomas Lodi also encourages those seeking a more integrative and alternative method of cancer treatment to contact the center through the website AnOasisOfHealing.com. The facility is located in downtown Mesa, Arizona and the website will provide you with further information on how to set up an appointment, what to expect during your first visit, travel information, and directions.
#_##
Press Contact: Clothilde Canale
Company Name: An Oasis of Healing
Phone: (480) 834-5414
Website: http://anoasisofhealing.com/
LegalView.com, your resource for everything legal, has introduced a new glossary of terminology relating to the condition mesothelioma located at http://mesothelioma.legalview.com/glossary.
(PRWEB) May 25, 2007 -- LegalView.com, your resource for everything legal, has introduced a new glossary of terminology relating to the condition mesothelioma. This terminology reference is intended to add to LegalView.com's full range of Mesothelioma resources. The glossary features hundreds of legal and medical terms and exists as a compliment to the site's articles and legal information related to mesothelioma.
The glossary, located at http://mesothelioma.legalview.com/glossary, adds to the already exhaustive resources related to mesothelioma located at LegalView.com. The glossary contains hundreds of terms and acts a companion piece to the full spectrum of mesothelioma related legal resources contained on LegalView.com's mesothelioma portal, which include articles, a mesothelioma blog, and various other bits of helpful mesothelioma legal information, as well as links providing access to mesothelioma legal advice.
Mesothelioma is a rare but fatally serious form of lung cancer that is nearly always connected to asbestos exposure. LegalView.com created its mesothelioma information portal as a free service for those looking for the latest news and information about mesothelioma and its effects, especially for mesothelioma patients and their families. This comprehensive glossary compliments the full range of articles and wide selection of links relating to mesothelioma lawsuits and mesothelioma claims, adding depth and value to the site's other legal resources. In addition to these mesothelioma legal resources, LegalView.com features a legal encyclopedia and links to helpful legal websites in each state.
LegalView.com stands on the cutting edge of approachable and useful legal content, and its new mesothelioma glossary is certainly no exception. Have questions about other legal matters? In addition to upcoming collections of legal resources related to auto accidents and practice areas for birth injuries and child injuries, LegalView.com also features extensive information on other legal issues such as automobile accidents, medical malpractice, occupational diseases and securities fraud. In addition, its attorney referral system allows parties looking for legal representation to get in touch with experienced lawyers quickly.
LegalView.com is a free public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz' Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez Hodes; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.legalview.com.
##.#
Press Contact: Peter Kent
Company Name: LegalView.com
Phone: 720-771-3246
Website: http://www.legalview.com
In a recent interview, a victim of Multiple Sclerosis revealed how she has been symptom-free for the past 10 years. The success she has experienced has compelled her to bring her research to the medical community in hopes of helping other MS sufferers. The National MS Society (backed by the pharmaceutical industry which funds it) has actively suppressed her.
Mount Jackson, VA (PRWEB) May 25, 2007 -- In a recent interview, a victim of Multiple Sclerosis revealed how she has been symptom-free for the past 10 years. The success she has experienced has compelled her to bring her research to the medical community in hopes of helping other MS sufferers. The National MS Society (backed by the pharmaceutical industry which funds it) has actively suppressed her.
MS has been extensively researched, yet it is still unknown exactly what causes it. The medical community has been focusing on the idea that it is an autoimmune disease since 1935. The common theory is that the immune system is attacking Myelin, the insulation on the nerves; however, there is no proof of this.
"I started studying histamine 2 and then started looking into how H2 is involved in heat. That was the first symptom I applied it to and then I started applying it to the other symptoms of MS. It answered all the symptoms of MS that we have not been able to answer, so from that I developed the treatment," says Elaine DeLack, RN.
DeLack found that Histamine 2 is a neuro transmitter that sends messages from nerve to nerve. It balances the immune system, makes digestive enzymes, regulates stress and stimulates the thyroid, to name a few essential tasks.
MS patients have difficulty taking the histamine in the brain and turning it into the H2 transmitter. This is why the MS sufferer's total body gets involved in the disease.
DeLack's own motivation was to try and find something to help alleviate her own debilitating MS symptoms. Through extensive research, DeLack developed and patented a treatment called Prokarin. She and numerous MS sufferers have found improvement in walking, dexterity, fatigue, cognition and bladder function to name a few common symptoms.
But simply helping herself and a few individuals was not her goal anymore. Once DeLack had helped herself, she wanted to help everyone suffering from MS. She knew that in order to help the most people, she would have to convince doctors that her treatment worked. This meant she would need to get a formal, double-blind study underway, and have it published in a scholarly, peer-reviewed medical journal. Yet she didn't count on the opposition that she would encounter from the very people who claimed to want to help MS sufferers the most.
Her studies were well-documented -- conducted through an impartial outside university. They showed conclusively the effectiveness of the very treatment which has kept her own body symptom-free for over a decade. The peer review process confirmed that her study was sound research and worthy of publication.
On the morning after its print in the MS Research Journal, the National MS Society sent out a release claiming that their own clinical review had determined that the study was poorly designed and hard to interpret. According to DeLack, the Society had not even gotten a copy of the report by the evening before their release. They never read it. They certainly never conducted a clinical review of it. They simply wanted it silenced, because they knew it threatened their interests.
While DeLack remains symptom free, her new goal is to someday cure MS for good. The biggest roadblock to success is the fact that current MS treatments, while less than effective, are huge cash cows for the drug providers who provide doctors with training and support organizations such as the National MS Society. DeLack continues her attempts to convince the medical community of the Prokarin treatment option.
You can hear her complete interview on Inside Success Radio, which earns its reputation for quality interviews with the best-known experts of many fields.
To listen to Elaine's interview with Rob Smith on Inside Wellness Success, visit http://www.insidesuccessradio.com/Guests/Elaine-DeLack
Media Contacts:
Debbie Wolf
Associate Producer
540-856-2555
#\##
Press Contact: Debbie Wolf
Company Name: Inside Success Productions, LLC
Phone: 540 856-2555
Website: http://www.insidesuccessradio.com/Guests/Elaine-DeLack
Based on recent research, the Brooks Center and its founder Ron Brooks have developed a new pain treatment and medical device. The center's neurovascular restructuring treatment and Neurovasc device technology were created to address, control and cure symptoms of physical pain and stress.
Westlake, CA (PRWEB) May 24, 2007 -- Ron Brooks, founder of the Brooks Center (www.brooksptcenter.com) in Thousand Oaks, California, has developed an innovative pain treatment and medical device as the result of a recent research program. The company is currently considering different private equity funding options to commence manufacturing and marketing of its neurovascular restructuring treatment and Neurovasc device technology.
During his 30 years of practice, Brooks became frustrated with the inability to control and cure the symptoms of pain, which hinders the rehabilitation process. He began to see a correlation between a specific pain pattern and the superficial structures of the body. Research in this area spawned the Brooks Center's neurovascular restructuring pain treatment.
A direct result of this research program was the development of the neurovasc, a unique vacuum device that restructures the superficial components of the body. The neurovasc eradicates pain by lifting and separating the layers of injured tissue, releasing entrapped nerves that cause pain. According to Brooks, the treatment also influences patients' brain chemistry and allows them to regain control over their lives when acute and chronic pain is relieved. With lower pain levels, patients report reduced stress, depression and anxiety levels; this also facilitates reducing patients' dependency on caffeine, alcohol and/or medication.
"Pain and stress compounded with substance abuse will eventually kill you," Brooks says. "The very tragic event involving Anna Nicole Smith focused public attention on this issue. The emotional factors that contributed to her death were obviously compounded by the abuse of some powerful medications. Perhaps this explains some of the bizarre behavior we saw before her subsequent overdose and death. This sequence of events is being played out in our country on a daily basis. We need to recognize that behaviors like this are a reflection and manifestation of a chemical imbalance in the brain."
Without finding ways to control pain and stress, the result is often a downward spiral from the accumulated effects, Brooks says. This often leads to increased dependency on caffeine, over-the-counter medications, drugs and alcohol to cope with pain and stress.
The Brooks Center is focused on the treatment of adults with physical pain and stress, and has recently expanded to become active in the field of adult and youth sports injuries. The Brooks Center is looking for partners to help build a network of offices to bring its neurovascular treatment to the public across North America.
See more information at www.brooksptcenter.com.
Brooks Center
1333 E. Thousand Oaks Blvd.
Thousand Oaks, CA 91362
#+##
Press Contact: Ron Brooks
Company Name: Brooks PT Center
Phone: 805-497-2294
Website: www.brooksptcenter.com
New and very affordable spas makes spring 2007 the perfect time to schedule a hot tub installation. Interested consumers can visit Repair-Home.com, an online resource connecting homeowners with top contractors and home repair specialists, for information about a range of hydrotherapy products to fit any budget. Repair-Home.com helps spa-seekers find contractor listings and links, get free estimates, and read important background information on common repair, renovation and home improvement projects like adding a hot tub or spa.
(PRWeb) May 24, 2007 -- Hydrotherapy options are available to consumers who couldn't previously afford it, and the outdoor hot tub season has arrived for the budget-conscious as well as for luxury-seekers. Because installing a hot tub can be difficult, complex and time-consuming, Repair-Home.com can help busy homeowners link to area contractors, get free estimates and have the hot tub installation complete by the summer solstice (http://www.repair-home.com/Hot_Tubs_and_Spas.html). Repair-Home.com is an online, interactive home repair resource for indoor and outdoor home improvement, repair and renovation projects.
In order to keep project costs in line, home owners who want to add a hot tub should interview contractors for help in mapping out their spa projects or hot tub additions, according to home improvement specialist Allison Beatty. "Repair-Home.com has a helpful hot tub directory where home owners can search for local contractors and get project planning advice," Beatty says.
Home spa and hot tub users reconnect with friends and family, reduce stress and may even sleep better, according to the National Sleep Foundation. Using a hot tub can relieve the pain of arthritis, miscellaneous aches and stiffness, and tension headaches, and they can also improve breathing by opening up nasal and bronchial passages. Hot tubs are also used by medical professionals to improve cardiovascular health, back pain and knee pain.
Repair-Home.com offers information and links to help homeowners sort through the many available options regarding hot tub installation. Hot tubs come in a variety of sizes and can be indoors or outdoors, free-standing or in-ground, and made of wood, fiberglass or acrylic. There are saltwater hot tubs that soothe the skin and even soft, inflatable hot tubs. Additional homeowner considerations include climate, budget, maintenance ability, and whether to do the work themselves or contract with a hot tub installation professional (http://www.repair-home.com/Hot_Tubs_and_Spas.html).
Repair-Home.com is an online home repair resource that includes an interactive homeowner driven forum, contractor listings and home repair resources ranging from walls and floors to cabinets and plumbing. Repair-Home.com connects homeowners with top home repair specialists and contractors for specific home repair projects.
#=##
Press Contact: JO VIOLET
Company Name: Repair-Home.com
Phone: 877-407-7377
Website: http://www.repair-home.com
Type 2 Diabetes May Not Need to be Managed with Avandia Or Other Drugs -- Treat The Disease Naturally & Safely
Skip the Drugs:
Treat Type 2 Diabetes Naturally & Safely by Curbing Sugar and Exercising, Cardiologist & Health Counselor Recommend
FOR IMMEDIATE RELEASE
May 22 2007 - NEW YORK-The shocking news this week in the New England Journal of Medicine that the diabetes medication Avandia may raise the risk of heart attacks by 43 % and cardiovascular death by 64 % draws attention to the fact that in many instances, preventing and naturally treating type 2 diabetes by reducing sugar and exercising are much safer than pharmaceuticals.
"Why isn't the medical community paying more attention to the fact that type 2 diabetes can be easily and effectively treated naturally, without any drugs?" wonders cardiologist Stephen T. Sinatra, M.D. and certified holistic health counselor Connie Bennett, C.H.H.C., authors of SUGAR SHOCK! How Sweets And Simple Carbs Can Derail Your Life-And How You Can Get Back on Track.
"Doctors and health experts need to focus on the dangers of high sugar intake and the corresponding alarming incidence of type 2 diabetes and insulin resistance," Bennett and Dr. Sinatra insist.
"Taking natural measures is a much easier and safer way to prevent type 2 diabetes," maintains Dr. Sinatra, an internationally recognized cardiologist and anti-aging expert with a practice in Manchester, Connecticut.
"And, if people get type 2 diabetes, whenever I can, I'll treat these patients with high blood sugar in natural ways such as restricting intake of sugar and simple carbohydrates, increasing fiber, exercising, losing weight, and targeted nutraceuticals such as cinnamon, alpha lipoic acid, magnesium, vanadium and gymnema sylvestre."
Both Dr. Sinatra and Bennett are alarmed that more doctors, patients and other consumers don't know that eating too much sugar can trigger many serious health conditions, including heart attacks, type 2 diabetes, cancer, obesity, and polycystic ovary syndrome. "Sugar is not your friend; it's your foe," says Dr. Sinatra, who downplays cholesterol's role in heart disease.
SUGAR SHOCK! (Berkley Books, 2007) is an expose about the dangers of sugars and refined carbs. For the book, Bennett, an experienced journalist, interviewed more than 200 health experts and sugar addicts from around the world, including researchers from Harvard and Princeton. The inspiration for SUGAR SHOCK! grew out of Bennett's own struggles with sugar addiction and her amazing improvement in health after kicking sweets and "culprit carbs." Dr. Sinatra was eager to join forces with Bennett, because for some 30 years, he's been warning his patients about sugar's dangers.
SUGAR SHOCK! includes a foreword by Dr. Nicholas Perricone, and it is endorsed by a Who's Who of health experts, including Dr. Mehmet Oz (YOU: On A Diet) and Gov. Mike Huckabee of Arkansas. To get a sneak peek at the book SUGAR SHOCK!, visit www.SugarShock.com, where you also can sign up for the weekly Stop SUGAR SHOCK! Minute e-zine.
#.##
CONTACTS: To interview Connie Bennett and Dr. Stephen Sinatra, contact connie@sugarshock.com; Heather Connor, at heather.connor@us.penguingroup.com and (212) 366-2004; or Heather Williams at williamsh@plannedtvarts.com and (212) 583-2729.
Connie Bennett (connie@sugarshock.com)
Stop SUGAR SHOCK!
No Mail
New York, NY
Phone : 1-866-542-5784
Is Avandia Going the Way of Vioxx?
More Information Press Room for www.SugarShock.com
Book Title : SUGAR SHOCK!
ICH-E14 guidance was finalized in May 2005. An important component of the guidance is the requirement of the Thorough QT Trial (TQT) in the development of new drug candidates. In this presentation, Dr. Joel Morganroth will provide "up-to-the-minute" insights into the ICH guidance and practical implications for implementation of the TQT.
Chicago, IL (PRWEB) May 18, 2007 -- Xtalks and eResearchTechnology are pleased to present the web conference ICH-E14 Two Years Later -- Trends in Design & Conduct of a thorough ECG Trial (TET), scheduled for May 31, 2007.
ICH-E14 guidance was finalized in May 2005. An important component of the guidance is the requirement of the Thorough QT Trial (TQT) in the development of new drug candidates.
The presentation will detail what has been learned in the first 90 TQTs, which may influence future study design and statistical approaches for such trials.
Dr. Joel Morganroth will provide "up-to-the-minute" insights into the ICH guidance and practical implications for implementation of the TQT. Comprehensive insight into emerging trends in TQT design, conduct and data analysis will be discussed in addition to the provision of an overview of the structure and function of the QTc Interdisciplinary Review Team of the FDA.
There is no cost to attend, register at: http://www.xtalks.com/ecgtrials.ashx
Pre-web Cast Questions
How does the ICH E14 guidance define which new drugs require a TQT before starting Phase III?
What has been learned about study design and analysis of Thorough QTc Trials over the past two years?
What technical and logistical requirements are required to conduct successful Thorough QTc Trials?
The ICH-E14 Two Years Later -- Trends in Design & Conduct of a thorough ECG Trial (TET) web conference takes place May 31, 2007, from 11:00 a.m. - 1:00 p.m. EDT.
Register at: http://www.xtalks.com/ecgtrials.ashx
Joel Morganroth, M.D., F.A.C.C., Chairman, Chief Scientist, eResearchTechnology, Inc.
Joel Morganroth, M.D. has an international reputation as a cardiovascular drug development specialist. Dr. Morganroth's experience includes memberships on Data Safety and Monitoring Boards for the National Institutes of Health and the Veterans Administration research programs and several major Pharmaceutical trials. He has published over 300 articles and edited nearly two dozen books and is frequently invited to lecture on a variety of cardiac and clinical research regulatory issues.
About eResearchTechnology:
eResearchTechnology (eRT) provides technology and services that enable life sciences industries to collect, interpret and distribute cardiac data accurately and efficiently. eRT is a leading provider of centralized electrocardiographic (ECG) services and supports the full-range of studies from single center to multi-center global trials across all therapeutic groups. eRT is an industry leader for Thorough QTc Trials (TQT), having completed significantly more than any other core lab. www.ertECG.com
About Xtalks
Xtalks is part of The Honeycomb Worldwide Group of Companies. Honeycomb Worldwide creates peer-to-peer business-oriented social networking communities, connecting senior level executives by delivering content through new and established media channels and is currently ranked 15th on the Profit Hot 50 List of emerging Canadian companies. www.honeycombworldwide.com.
For more information on this conference or Xtalks in general, or to enquire about speaking opportunities or sponsoring future events, visit www.xtalks.com or contact Karen Anderson, Chief Marketing Officer, at phone: 312-977-1166, x. 1209.
Register at http://www.xtalks.com/ecgtrials.ashx
#*##
Press Contact: KAREN ANDERSON
Company Name: Xtalks
Phone: 312-977-1166
Website: http://www.xtalks.com/ecgtrials.ashx
Battle Of The Sexes: Men's Health Vs. Health
by Phyllis Fine, Wednesday, May 16, 2007
SO which gender has the best guide to hotter sex, tighter abs, and cancer prevention? We pitted Rodale's Men's Health, the major male-oriented health pub (although 16% of its circulation is female), against Time Inc.'s Health, which is totally targeted to women. (We could've gone with such powers of the women's general health field as the veteran Prevention, or relative newbie Women's Health, but both are also published by Rodale, and we wanted to make this a two-publisher contest.)
Here's how each mag stacks up.
Better orgasms department: Health, B; MH, A-. MH's pieces on sex are, not surprisingly, more graphic than Health's, with an attention to detail that could be helpful even to the most sophisticated guy. Take the very specific tips on foreplay and giving "her the best orgasm of her life" in May's "How To Be The Perfect Guy For Her." "Her Eyes Say Maybe, But Her Brain Says..." has the admirable goal of explaining how a woman's brain triggers sexual response. But despite the author's clear, entertaining style, all those anatomical details can be heavy going.
Health's more ladylike entry is a cute first-person piece about using tips from sex manuals, which breaks up the earnestness of the May issue with some welcome humor. Then there are the results of Health's sex survey, which the editors call surprising, but I call ho-hum. OK, except for some of the answers to "What's the craziest place you've had sex?" Gotta wonder why the couple getting it on at Disneyland wasn't put off by those giant rodents.
Lose 30 pounds in 10 days dept.: Health, B; MH, C. The challenge here is to provide a fresh angle on weight loss, that most-hackneyed topic -- the mainstay of not only general health books but all those fitness pubs as well.
MH's tips from "modern food science" -- like, the smaller the plate, the less you'll eat -- may not be front-page news, but at least they're being offered to a readership that isn't to the diet born. For most women, Health's suggestions to save calories by using mustard instead of mayo, and skipping cream and sugar in coffee, are laughably obvious.
More helpful -- and fresh: Health's feature on "former fat girls," which provides tips straight from former dieters themselves, and its roundup of new, healthful convenience foods.
Studies show 100% of leaves are green dept.: Health, B-; MH, C. Short items on scientific studies should provide cutting-edge info. Too often, they're merely fillers, the dregs of all health mags. MH rates lower in this category because it reports on even more studies with stupid conclusions. For example, "Women's desks harbor three to four times more germs than men's desks do," because women are more apt to keep food in their drawers.
Most useful info: Health gets extra credit for this category. Since heart disease runs in my family, I found the piece on women and heart attacks particularly relevant. I'm getting a stress test soon, and it was reassuring to read that this procedure can detect a precursor endemic to women's heart disease.
Features and writing quality: Health, B - ; MH, B+. I'd pick up MH first if it was sitting in my doc's waiting room, because it's usually a more entertaining read, with humor and a real voice -- even if it's a hey-buddy-we're-all-in-this-together tone that's very different from my female sensibilities. Its lead features can be too long, but they make scientific knowledge relevant and palatable. For example, the excellent piece on organ donation in the December issue not only moved me (it was framed around the death of the author's father) but taught me some facts, that I may someday, unfortunately, have to grapple with.
Health's lack of compelling angles on evergreen topics (in May, the benefits of deep breathing, and how to get more energy) means I can skim through an issue, put it down, and not remember a thing. Only two pieces in the May issue were memorable stylistically: the aforementioned sex manual article, and a breast cancer survivor's account of how she bared her implants to soothe the anxieties of a woman considering a double mastectomy.
Relationship Advice: Health, C-; Men's Health, B-. Both mags offer clichés in this area, though MH at least offers flashes of wit and insight. In Health's predictably boring world, even if "your husband left his wet towel on the bed -- again," you're advised to let it go and learn to focus on his good points.
But what if that slob took the "Will She Forgive You?" quiz in the December MH? I'd have a harder time saying "honey, that's OK," because writer Sarah Miller (a traitor to her gender) suggests that he tell some whoppers. (The photo of his lap dance at the bachelor party was just a photo-op to please the groom?)
Look of the books: Health, B; MH, B. Neither mag is gorgeous -- but not terrible, either. Both have some outstanding photos, especially Health's candid-looking mother and daughter shots illustrating the interviews in "What My Mother Taught Me."
Both covers are too cluttered, though -- and what the hell is the Health model on the May cover doing with that hand raised awkwardly behind her head? MH at least stands out on the newsstand with its black-and-white cover.
Bottom line: Both pubs provide some useful features. I'd rather read MH because its articles are more literate and memorable, but if you're a woman, Health occasionally comes through with some relevant specialized information.
MAG STATS
Health
Published by: Southern Progress Corp., a wholly owned subsidiary of Time Inc.
Frequency: Monthly
Web site
Men's Heath
Published by: Rodale
Frequency: 10 times a year
Web site
Phyllis Fine is columns editor for MediaPost.
Magazine Rack for Wednesday, May 16, 2007: http://publications.mediapost.com/
--------------------------------------------------------------------------------
If this issue was forwarded to you and you would like to begin receiving a copy of your own, please visit our site - www.mediapost.com - and become a complimentary member.
For advertising opportunities see our online media kit.
--------------------------------------------------------------------------------
We welcome and appreciate forwarding of our newsletters in their entirety or in part with proper attribution.
(c) 2007 MediaPost Communications, 1140 Broadway, 4th Floor, New York, NY 10001
PharmaPlusOnline.com, an offshore pharmacy will be launching its highly anticipated website on May 15th 2007. PharmaPlusOnline.com brings a strong presence in providing a simple and unique experience by giving consumers a choice to branded or generic pharmacy medications.
Phoenix, AZ (PRWEB) May 16, 2007 -- PharmaPlusOnline.com, an offshore pharmacy will be launching its highly anticipated website on May 15th 2007. PharmaPlusOnline.com brings a strong presence in providing a simple and unique experience by giving consumers a choice to branded or generic pharmacy medications.
A Pharma Plus Online spokesperson said, "Pharma Plus Online is here to fill the needs of the ever growing consumer dissatisfaction with their local pharmacy. Having the price of your prescription drugs increased, or purchasing online and receiving dangerous or counterfeit drugs is all too common and is simply not acceptable for any consumer. Pharma Plus Online believes in respecting its clients and respecting their privacy. Consumers have been abused too long and too often as can be noted when complaint sites keep growing steadily everyday."
Pharma Plus Online enables consumer to receive their prescription drugs discreetly, quickly and cost-effectively. PPO believes that the customer has the absolute right to choose where they obtain their personal medications. By providing the consumer with that freedom of choice coupled with an excellent professional service and real confidentiality they aim to dispel the myths about buying prescription drugs online. Importation of prescription medicines is allowed in most countries providing that the medication is for personal use and does not exceed a three month supply.
By introducing this service it will fundamentally the change the way online pharmacies work and will be immense for its clients who need this service. PPO has developed comprehensive delivery systems which work efficiently and comply with most countries importation regulations. PPO's team is fully efficient and confidential when it comes to shipping orders in the USA or Europe. All of the products they distribute are manufactured by the world's leading pharmaceutical companies. Indeed the very same manufacturers that supply medications to your local pharmacy!
Pharma Plus Online offers a unique 3-D protection for its clients and virtually eliminates any attack on the client's privacy. All orders are received via a secure server, protected by 128bit encryption, to ensure the consumers details are kept private.
Pharma Plus Online will also be providing its unique pharmacy affiliate program. The program is remarkable in rewarding members repeatedly as their referrals; unlike current companies who simply provide a one time referral bonus. PPO strives to become the global leader in online pharmacy by providing critical services missing in the industry today: consumer privacy y, intelligent customer service and competitive prices to meet the demands of consumers.
About Pharma Plus Online
PPO is administered by a major Pharmaceutical Organization based in Europe and Asia. Management team is located offshore and they are committed in providing a safe and simple purchase online. With its reputable reputation as a reliable and discreet pharmacy it has made the company as one of the top offshore pharmacy there is.
##!#
Press Contact: Matthew Richardson
Company Name: Pharma Plus Online
Phone: 1-888-500-2401
Website: www.pharmaplusonline.com
The Pharmacy Verification Network is now available to pharmacy owners and operators who wish to begin creating and managing pharmacy profiles online.
Alexandria, VA (PRWEB) May 14, 2007 -- ChainDrugStore.net has launched the Pharmacy Verification Network (http://www.pharmacyverification.com) to provide an online single-source, secure database of pharmacy-managed profiles required for verification and credentialing by healthcare partners.
For pharmacy owners and operators, the Pharmacy Verification Network provides an easy and secure way to share pharmacy profiles with pharmacy benefit managers, managed care organizations and health plans that credential their pharmacies. In addition, the network alerts pharmacy owners and operators when industry data sources report information that differs from their pharmacy profile on the network.
Pharmacy benefit managers, managed care organizations and health plans will be able to query the Pharmacy Verification Network by pharmacy type, location, services offered and more. Custom reports and data downloads will be delivered in multiple formats, including ad-hoc downloads to meet specific data needs.
"We have heard from both our pharmacy and healthcare members that pharmacy credentialing is a major pain point. It is costly and time consuming to all involved," said Todd Grover, ChainDrugStore.net's president. "The Pharmacy Verification Network" is intended to simplify the sharing of credentialed pharmacy information and provide the most accurate collection of pharmacy profiles in the industry."
The Pharmacy Verification Network is now available to pharmacy owners and operators who wish to begin creating and managing pharmacy profiles online. In August 2007, the network will be available to pharmacy benefit managers, managed care organizations and health plans.
About ChainDrugStore.net Inc.
ChainDrugStore.net is the link to pharmacy an online communications network manufacturers, managed care organizations, pharmacies and regulatory agencies use to communicate and aggregate pharmacy critical product information.
Learn more about the benefits associated with being part of the ChainDrugStore.net network. Visit http://www.chaindrugstore.net
##(#
Press Contact: Pam Burkhardt
Company Name: ChainDrugStore.net
Phone: 703-837-8311
Website: www.chaindrugstore.net
Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ -- ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate, may have potential as a chemopreventive agent, according to world-renowned mesothelioma researcher Michele Carbone M.D., Ph.D., at this week's American Association for Cancer Research (AACR) Annual Meeting.
In a series of poster presentations, Dr. Carbone highlighted the growing worldwide problem of asbestos exposure and its link to malignant mesothelioma. Dr. Carbone presented data that show the early detection in patients at high risk for developing malignant mesothelioma is becoming more prevalent via the presence of certain biological markers in blood samples. Furthermore, he pointed out that ONCONASE's favorable toxicity profile and its well-documented mechanism of action, which directly affects the pathway that has been shown to cause asbestos carcinogenesis, position ONCONASE for potential early administration to populations "at-risk" for mesothelioma. If clinically validated, such a new approach might enable physicians to use ONCONASE as a chemopreventive agent to potentially prevent the onset of mesothelioma, or reduce the doses of cytotoxic agents needed in those patients who develop the disease.
"The potential of ONCONASE as an early first-line preventative treatment for mesothelioma is an exciting development that we plan to investigate through clinical trials," said Dr. Carbone. "With approximately more than 25 million asbestos exposure cases reported worldwide, we believe that ONCONASE might play a greater role in the treatment protocols for a much larger population than was originally envisioned for this dismal disease."
Dr. Carbone is a professor and director of the thoracic oncology program as well as a clinical professor of pathology with the University of Hawaii's Cancer Research Center of Hawaii, and chairman of the Alfacell Thoracic Advisory Board. Previously, Dr. Carbone was Director of the Thoracic Oncology Program at Loyola University in Chicago, where he is also a tenured Professor at the Cancer Center, Department of Pathology. He also held scientific and academic positions at the National Institutes of Health (NIH), and at the University of Chicago.
Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "Dr. Carbone is recognized as one of the world's leading researchers in mesothelioma. His remarks about ONCONASE at the AACR Annual Meeting reflect the interest of the international medical community in expanding the potential uses of ONCONASE."
About ONCONASE(R)
ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact:
David Schull or Wendy Lau Andreas Marathovouniotis
Noonan Russo Noonan Russo
212-845-4271 212-845-4253
david.schull@eurorscg.com andreas.marathis@eurorscg.com wendy.lau1@eurorscg.com
CONTACT: David Schull or Wendy Lau, +1-212-845-4271, or, or , or AndreasMarathovouniotis, +1-212-845-4253, or , all ofNoonan Russo david.schull@eurorscg.com wendy.lau1@eurorscg.com andreas.marathis@eurorscg.com
Web site: http://www.alfacell.com/http://www.noonanrusso.com/
In accepting Planet Drug Direct into its prescreened online pharmacy directory, eDrugSearch.com has added the pharmacy's inventory of prescription drugs to the eDrugSearch.com database of 30,000 prescription drug listings.
San Antonio, Texas (PRWEB) May 12, 2007 -- eDrugSearch.com, a free search engine and online community for Americans interested in purchasing safe, low-cost prescription drugs from prescreened Canadian pharmacies and other prescreened international pharmacies, announced that is has accepted Planet Drug Direct into its pharmacy directory. In accepting Planet Drug Direct into its directory, eDrugSearch.com has added the pharmacy's inventory of prescription medications into the eDrugSearch.com database.
"Because Planet Drug Direct is properly licensed and meets eDrugSearch.com's standards of quality and professionalism in online pharmacies, we have accepted its inventory of prescription medications into the eDrugSearch.com database," said Cary Byrd, president of eDrugSearch.com.
With more than 30,000 drug listings, eDrugSearch.com brings together licensed and accredited pharmacies from around the world in one comprehensive, easy-to-use database. The pharmacy page for Planet Drug Direct is located at: http://www.edrugsearch.com/pharmacies/planet-drug-direct.html .
While many Americans are interested in Canadian pharmacies or other international pharmacies as a means of saving money on their prescriptions, they are often concerned about whether they can trust the quality and safety of the prescription medications they find online. eDrugSearch.com addresses these concerns by only accepting online pharmacies in the eDrugSearch.com database that pass a rigorous prescreening process -- including proof of home-country government licensing and third-party accreditations.
eDrugSearch.com expects to increase online prescription drug listings in the eDrugSearch.com database to 100,000 later this year -- making it easily the most comprehensive resource of its kind.
Additionally, eDrugSearch.com offers up-to-the-minute price search, extensive information on drugs and medical conditions and other features that make it the most advanced destination for online pharmacy consumers. Consumers can register for a free membership with eDrugSearch.com at the following url: http://www.edrugsearch.com/members/register-member.php .
Popular medications available through the eDrugSearch.com database include:
- Accupril
- Actos
- Ambien
- Avandia
- Buspar
- Cephalexin
- Evista
- Lamisil
- Lotensin
- Monopril
- Naproxen
- Prednisone
- Prinivil
- Prozac
- Remeron
- Risperdal
- Wellbutrin SR
.. along with thousands of other listings.
About eDrugSearch.com
Based in San Antonio, eDrugSearch.com is the Internet destination for those seeking the cost benefits, enhanced privacy and convenience of ordering prescription drugs online from licensed international pharmacies, primarily in Canada. eDrugSearch.com's advanced search features allow members to identify pharmacies with specific licensing requirements and third-party accreditations. eDrugSearch.com is an impassioned advocate for consumers interested in lower drug prices. Visit the company's Web site at www.eDrugSearch.com or the eDrugSearch Blog at www.edrugsearch.com/edsblog .
## _ #
Press Contact: Cary Byrd
Company Name: eDrugSearch.com
Phone: 972-235-3439
Website: http://www.edrugsearch.com
Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative. This follows as a natural reaction to already successful offshoring activities in the IT industry.
Minneapolis, MN (PRWEB) May 10, 2007 -- Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative. This follows as a natural reaction to already successful offshoring activities in the IT industry. The big question is: Do clinical research capabilities comparable to the US in terms of sophistication and FDA-compliance exist anywhere else in the world? And if they do, are they ready to handle the huge surge in business likely headed their way?
Outsourcing Clinical Trials: A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index analyzes the key drivers that have made the search for effective clinical trial outsourcing a necessity rather than an option in today's drug development efforts. The current climate of clinical trials in emerging markets across the world is examined. Geographic areas covered include Europe, Latin America, Australia and New Zealand, Africa, Asia and India.
The report also includes the Clinical Trial Outsourcing Global Attractiveness Index. This vital piece of original research includes tables and graphs which rank international locations, according to the following criteria:
Study Cost Indicators
Patient Indicators
Disease Indicators
Clinical Research Indicators
Research Personnel Indicators
Study Site Indicators
Business Environment Indicators
The index serves as an invaluable starting resource for pharmaceutical companies seeking to outsource their clinical trial functions to international destinations.
Report Highlights
Why Outsource Clinical Trials?
More and more pharma executives are considering outsourcing clinical development as an effective means to make the process cheaper and more efficient. Another attraction of outsourcing clinical development is that it can be implemented relatively quickly. This trend towards outsourcing clinical drug development has already started. Industry analyses of budgetary outlay on clinical outsourcing further support this statement.
Outsourced pharmaceutical R&D spending will grow almost 15% annually for the next five years. The increase forecasted for outsourced spending in the coming years is about double the anticipated increase in general R&D spending. Pharmaceutical companies are finding that by using outsourcing strategically and by effectively integrating external resources with internal capabilities, they can reap dividends by getting better products to market faster.
Reasons why outsourcing is growing as an attractive option:
Overcoming deficiencies in internal capabilities;
Reducing financial risk by limiting capital investments such as lab equipment and real estate;
Allowing biotech companies to hold off from partnering with a major pharmaceutical company, thereby enabling them to keep a larger ownership interest in a new drug;
Saving significant time and money in the approval process with improvements in quality and speed;
Enabling companies to pursue approval in a number of countries at the same time by utilizing an international CRO.
Promotes greater specialization.
Some reasons for a decreasing pool of U.S. based investigators:
High turnover rate- many investigators are not interested in conducting more trials after the first or second round
Lack of financial incentives- there has been flat growth in study grant amounts
Growing protocol complexity
Onerous burden of compliance
Slow payment process
Reasons for increasing reliance on non-U.S. investigators:
Training is comparable to western counterparts and there has been a tremendous surge in efforts to improve cGMP education and compliance training
Compensation costs are significantly less
Socially and culturally more acceptable to populations in emerging markets - this is important to ensure high patient compliance
Affords access to large patient populations - this promises long term growth as there is no immediate threat of diminishing numbers of treatment-naïve subjects
Contract Research Organizations and Outsourcing
During the past few years, contract research organizations, or CROs, have received the lion's share of outsourced clinical research revenue. In 2001, in the United States, CROs received an estimated 60% of the clinical research outsourced from pharmaceutical companies. The CRO market grew from $1 billion in 1992 to more than $8 billion in 2002. CROs enrolled 7 million research subjects in 1992 and 20 million in 2001.
The multi-national availability of CRO services is increasing in the wake of two concurrent trends - the globalization of outsourcing services in general, following the lead of the financial and Information Technology (IT) sectors, and the internationalization of the pharmaceutical sector in the quest for global market reach, which has been facilitated by the International Conference on Harmonization (ICH) and expansion of international trade, travel, and communication.
Trends and Outlook
Recent restrictions, due to heightened security procedures, will increase the need to have a physical presence overseas due to barriers to the importing of foreign talent into the US and the increasing cost, time, and difficulty of moving people and supplies about internationally. Only about one-fifth of respondents provided services internationally in 1998. Over the succeeding years, however, the number of US-based CROs reporting that they had opened up offices overseas rose from one-quarter to one-third.
The location of these offices (11 in 2000 and 20 in 2002), as shown in Graph 2.7, appear to encompass regions considered both "traditional" (e.g., Europe and North America) as well as "non-traditional" (e.g., Asia and Africa) loci for clinical trials. The most significant change from 2000 to 2002 appears to be the increase in offices being opened in Australia, perhaps at the expense of new office openings in Asia. This could be a harbinger of the emergence of Australia as a hub for the provision of CRO services in the Asia-Pacific region.
Furthermore, our survey results indicate that this expansion overseas is particularly evident in the clinical area, with 44% of US-based respondents indicating that the number of clinical trials conducted overseas has increased over the last two years, while only 6% reported that it has decreased.
# : ##
Press Contact: SALES DEPT
Company Name: Arrowhead Publishers
Phone: 1-866-397-1376
Website: http://www.arrowheadpublishers.com/reports/clinical-trials/outsourcing-clinical-trials/
Leading physician and author of best-selling medical books partners with Detoxologie.com to heighten awareness of need for ongoing cleansing program as part of an overall preventative health plan.
Englewood, CO (PRWEB) May 10, 2007 -- Hyla Cass M.D., an expert in integrative medicine who has authored several books, including Natural Highs and 8 Weeks to Vibrant Health, has partnered with Detoxologie.com to draw attention to the positive benefits of preventive health care, including internal cleansing.
"As a practicing physician, experience has taught me that prevention is the best method for health maintenance," Dr. Cass explains. "Since the digestive system is the first entryway for many toxins and pathogens (such as bacteria and parasites), regular detoxification is a requirement for optimal health. I have found Detoxologie to be one of the most comprehensive and effective colon cleansing programs available."
Dr. Cass, a nationally acclaimed innovator and expert in the field of integrative medicine, combines the best of leading-edge natural medicine with modern science in her clinical practice, writings, lectures and nationwide media appearances, most recently on ABC's top-rated daytime show The View.
As Dr. Cass stresses, detoxification is a normal, natural, and necessary part of daily well-being and health maintenance. Because of this, detoxification should be done on a consistent basis, and supported by ongoing efforts through diet and supplementation, using such products as Detoxologie's high-potency 30-Day Body-Cleansing and Renewal Program.
A member of the Medical Advisory Board of the Health Sciences Institute and Taste for Life magazine, and an Associate Editor at Total Health Magazine, Dr. Cass supports detoxification because once the body is cleansed and functioning more efficiently, it will absorb more nutrients from foods, allowing users to finally side-step destructive cravings for "bad" carbohydrates and saturated fats.
"It's a win-win situation," explains Detoxologie owner Steve Franzmann, who has suffered four strokes, the first at the age of 35. After years of extensive evaluation, Steve's medical condition was diagnosed as Lupus Anti-Coagulation Syndrome, a genetic blood disorder. During this time, rather than take multiple prescription medications that only seemed to make matters worse, Steve and wife Kelley teamed up with master herbalist Bob Nikkel in search of a natural alternative. The remarkable improvement in Steve's health led to the creation of the Detoxologie product line, which safely and quickly eliminates toxins from not only the digestive tract, but the organs and very cells themselves, providing Steve and other users alike with a more solid foundation on which to build better health.
In repairing Steve's health and helping others do the same, the Franzmann's have consulted with some of the nation's foremost experts on integrative medicine and naturopathic treatments. Their research and findings on the importance of internal cleansing and detoxification has led to ongoing improvements in Steve's personal health. This remains the driving force behind their commitment to providing education and a product line that will help others find health as well, an unwavering commitment they share with Dr. Cass.
About Detoxologie (http://www.detoxologie.com)
Detoxologie is a subsidiary of Triesca International LLC. Detoxologie is dedicated to providing safe and effective products to cleanse and detoxify the body. By offering the most comprehensive and effective herbal supplements, focusing primarily on "whole-body" detoxification and backing it up with a no questions asked-100% money back guarantee, Detoxologie aims to become the leading online retailer of internal cleaning products.
Media Contact:
Kelley Franzmann
triesca @ gmail.com
## - #
Press Contact: KELLIE FOWLER
Company Name: Detoxologie
Phone: 613-326-0563
Website: http://www.detoxologie.com
The statistics surrounding the prevalence of headache sufferers in the United States are astounding. Magnetic therapy offers an effective, non-drug alternative for chronic and severe headache sufferers.
Palm Desert, CA (PRWEB) May 10th, 2007 - According to the American Headache Society, every ten seconds someone in the United States goes to the emergency room with a headache or migraine. Almost 50 million Americans suffer from chronic headaches. With statistics this astounding, it is no wonder that new medications are constantly introduced claiming to prevent and cure the pain and frequency of headaches.
Despite the prevalence of new headache treatments, statistics continue to show that they are not working and a miracle drug for headaches has yet to be found.
However, a drug free alternative is improving the lives of thousands of Americans. "Last year, a friend recommended that I try magnetic therapy to help chronic headaches," comments Darlene Whyte from Corpus Christi, Texas. "I did some research and discovered Dr. Bakst who is considered by many to be the preeminent expert on magnetic therapy. I purchased the Gold Neomax Bezel and felt almost instant relief. My life has improved tremendously, I wear my Bezel everyday and it provides continuous prevention."
Dr. Bakst founded MagnaTech Labs in 1994 and since then, they have created the only patented magnetic pain relief technology. Dr. Bakst explains how magnets are an effective headache treatment: "There is no such thing as pain if it doesn't reach the brain. A pain impulse must reach the brain to be determined as pain. You can block the transmission of the pain impulse to the brain using drugs or magnetic therapy. By placing a highly powerful negative magnetic field over the nerve, the magnetically, positively charged ions will be attracted to the negative magnetic field, thus impeding the flow of the positively charged ions along the nerves to the brain. Of course, some of the positive ions will escape, thereby allowing continued sensation. However, our research reveals that the longer the magnets are in place over the affected site, the more effective the negative magnetic field will become. Thus, the longer the product is used, the more effective it becomes."
Many of Dr. Bakst's clients have suffered from chronic and severe headaches for years. Once wearing the Neomax Bezel, they find that their headache usually subsides within about 20 minutes. If they continue wearing the necklace, as Dr. Bakst explained, the product becomes even more effective. It is an amazing headache treatment offering long-term relief, without the dangers associated with prescription and over the counter drugs.
Headache sufferers interested in learning more about how magnetic therapy is a beneficial alternative headache treatment are strongly encouraged to visit the company's website at www.drbakstmagnetics.com.
About Magnatech Labs Inc:
Magnatech Labs, Inc., was founded and established by Dr. Alvin Bakst in 1994. Since its inception, the company has been dedicated to researching effective methods of alleviating and eliminating pain in the body without the use of drugs or invasive medical procedures. It has received the only U.S. patent for pain control issued by the U.S. patent office (5,707,333).
Magnatech Labs, Inc. has developed and now manufactures the highest quality magnetic pain relief products available on the market using both ceramic and neodymium magnets placed in a supportive neoprene material to provide maximum comfort and support.
# = ##
Press Contact: Sally Stewart
Company Name: Magnatech Labs Inc
Phone: 760-341-5077
Website: www.drbakstmagnetics.com
A new automated drug management system in the newly remodeled inpatient pharmacy at the Nebraska Medical Center is drawing a lot of attention as it minimizes the potential for medication errors and improves patient safety.
Omaha, Neb. (PRWEB) May 9, 2007 -- The newest employee in the newly remodeled inpatient pharmacy at The Nebraska Medical Center is drawing a lot of attention. This worker stands 8 feet tall, spans a width of 36 feet and holds the key to ensuring greater patient safety, reducing medication errors and increasing productivity - giving pharmacists more time to spend consulting with physicians and nurses about patient care and medication safety.
It's the Swisslog PillPick system, an automated drug management unit, designed to package, store and dispense medications in bar coded, unit-dose form. It has the capability of storing 44,000 medication unit doses. The Nebraska Medical Center dispenses more than 6,000 unit doses daily.
"Less than 1% of acute care hospitals in North America have this technology," said Mike Powell, executive director of pharmacy and pathology services at The Nebraska Medical Center. "The Nebraska Medical Center is fortunate to have such state-of-the-art technology. This system will definitely help eliminate possible medication errors."
Automated packaging and dispensing systems for filling patient orders are becoming more common in U.S. hospitals as a result of increased public knowledge related to medication errors. The Institute of Medicine reports that more than 7,000 deaths result from medication errors in our country alone. While some of the medication errors result from incorrect orders and transcriptions, almost half of the medication errors occur because of dispensing errors or administration errors.
Bar coding has the potential to dramatically reduce medication errors during dispensing and administration. "Accurate dispensing is key to patient safety and automatic picking based on bar code recognition assures us of that. The robot also offers compact and efficient storage," said Powell. "Additionally, bar codes will help our hospital make sure that the doctors and nurses are administering the right drugs at the appropriate dosages," said Powell.
According to a VA-authored article published in the Journal of Healthcare Information Management (Volume 16-1, Winter 2002), the Colmery O'Neil VA Medical Center in Topeka, KS reported bar code implementation decreased the following error types:
Wrong medication by 75%
Wrong dose by 62%
Wrong patient by 93%
Wrong administration time by 87%
Missed doses by 70%
"The reduction of medication errors has an obvious patient impact and has a financial
benefit too," said Powell. "As a general rule, each adverse drug event due to medication errors can add more than $5,800 to the hospital bill of a single patient." Powell said the cost stems from factors including increased hospital stays, drugs used to counteract incorrect dosages, and extra nursing and physician costs.
A critical component to bar code implementation happens at a patient's bedside. In a typical administration cycle utilizing bedside verification, a nurse will scan the bar code on the unit dose and scan the patient's wristband in order to ensure that the "five rights" are met: right patient, right drug, right dose, right route, and right time. The nurse also will scan the bar code on her hospital identification badge to record who administered the drug.
Dawn Straub, RN, MSN, CNAA, BC, director of nursing resources and development at The Nebraska Medical Center says it is vitally important that pharmacy and nursing work closely together. "Nurses are at the sharp end of patient care delivery - that point where all preceding work and actions of others culminate into actual intervention to the patient. Bar coding will help provide patient safety at this point of interaction, and give the nurse a safety net."
Another safety feature of the PillPick system is full automation. After a Pillbox is filled and verified by the pharmacist, the doses dispensed are not touched by human hands until they are given to the patient. A PillBox contains up to a three-month supply of commonly dispensed pharmaceutical drugs.
"Simply put, the more human intervention, the greater the probability for error. This automated system minimizes handling by pharmacy staff, reducing the potential for human error," said Powell. The 'robot' has been operational at The Nebraska Medical Center for a month now. "Already, the pharmacy staff is seeing amazing results," said Chris Shaffer, director of pharmaceutical and nutrition care at The Nebraska Medical Center. "One big difference is the phones aren't constantly ringing in the pharmacy anymore because nurses aren't calling about missing medication doses. We estimate the PillPick system will eliminate about 17,000 phone calls a year."
Shaffer adds the system also eliminates the tedious and time-consuming task of handling and packaging unit dose medications. This frees up pharmacists to spend more time consulting with physicians and nurses about patient care. "Research shows that when pharmacists round with physicians, medication errors are reduced by up to two-thirds," said Shaffer.
Pharmacy Quick Facts
The hospital inpatient pharmacy fills around 2,000 new medication orders each day.
The hospital inpatient pharmacy dispensed more than 2.2 million unit doses of medications last year.
With a reputation for excellence, innovation and extraordinary patient care, The Nebraska Medical Center has earned the J.D. Power & Associates highest healthcare honor - Hospital of Distinction. It has also been recognized with the 2006 Consumer Choice Award, a mark of patient satisfaction as selected by healthcare consumers. As the teaching hospital for the University of Nebraska Medical Center, this 689 licensed bed facility has an international reputation for providing solid organ and bone marrow transplantation services and is well known nationally and regionally for its oncology, neurology and cardiology programs. The Nebraska Medical Center can be found online at www.nebraskamed.com.
# * ##
Press Contact: Andrea McMaster
Company Name: Nebraska Medical Center
Phone: 402-559-7037
Website: http://www.nebraskamed.com/
Medicis Pharmaceutical Corp. will pay $9.8 million to settle allegations that it promoted the use of a topical skin preparation for unapproved use.
Overland Park, Kan. (PRWEB) May 9, 2007 -- "Medicis Pharmaceutical Corp. will pay $9.8 million to settle allegations that it promoted the use of a topical skin preparation for unapproved use," the United States Department of Justice said Tuesday (Case 04-2389 in federal court in Kansas).
The four whistleblowers, represented by Brous Horn LLC of Overland Park, Kan., informed the government of the pharmaceutical company's allegedly illegal marketing practices that resulted in the settlement.
The four were former Medicis sales representatives who alleged that Medicis trained them to market one of its drugs to doctors for an off-label use, not approved by the Federal Drug Administration (FDA).
The whistleblowers alleged that they were trained to market a prescription drug called Loprox to pediatricians for use on children under the age of 10 to treat diaper rash and other skin conditions. The FDA has never approved the use of Loprox on children under the age of 10.
"Although doctors can prescribe medications to patients for off-label uses," says attorney Carrie Brous, Brous Horn, Overland Park, Kan., "it is illegal for pharmaceutical companies to market their drugs to doctors for off-label uses."
Medicis allegedly misused federal and state funds by marketing Loprox off-label to doctors, causing claims to be submitted to Medicaid for Loprox dispensed for the treatment of children under 10 years of age.
"Because of the False Claims Act, the four whistleblowers will receive a portion of the $9.8 million settlement as a reward for coming forward with information," says Brous.
The Act was first enacted by Congress in 1863 during the Civil War amid widespread fraud on the Union military by suppliers who would, for example, charge the government twice for the same cavalry horse. The Act encouraged reporting of the fraud by private citizens by providing a 50 percent reward to the whistleblower. The act was scaled way back in 1943, but Congress sweetened it in 1986 as a reaction to reports of widespread fraud and Cold War defense spending under President Ronald Regan. The Act now provides for a 15 to 30 percent reward to whistleblowers.
Brous Horn LLC is a plaintiffs' law firm specializing in commercial, employment, and serious personal injury litigation. Since 2003, Brous Horn has been serving clients in the Kansas City metropolitan area and nationwide. The Brous Horn office is located in Overland Park, Kan. For more information, please contact Carrie Brous or Tammy Horn at 913.897.7877 or visit their website at www.broushorn.com.
## % #
Press Contact: Melissa Sandfort
Company Name: Brous Horn
Phone: 816-474-3166
Website: www.broushorn.com
"microRNA: Biology, Function & Expression" (ISBN: 1933255196) by Neil J. Clarke, PhD and Philippe Sanseau, PhD, scientists at GlaxoSmithKline, and a team of academic, pharma, and biotech collaborators has been just published by DNA PRESS. Providing a comprehensive overview of a fast-emerging field, this volume dedicated to the biological role of microRNAs (miRNAs) discusses methods for identifying and characterizing their functions and looks at potential applications of miRNA research in medicine and pharmacology. MicroRNAs (miRNAs) are small, noncoding RNA molecules that appear to regulate gene expression. Found in plant and animal species and possibly traceable back to ancient forms of life, miRNAs are now estimated to regulate a third or more of genes in the human genome.
Eagleville, PA (PRWEB) May 8, 2007 -- Today, DNA Press announced the publication of "microRNA: Biology, Function & Expression" (ISBN: 1933255196) by Neil J. Clarke, PhD and Philippe Sanseau, PhD, scientists at GlaxoSmithKline, and a team of academic, pharma, and biotech collaborators as part of the DNA Press Nuts & Bolts series.
MicroRNAs (miRNAs or miRs), are an abundant class of small (approximately 22 nucleotides in length), non -protein -coding RNAs (sncRNAs) that appear to play important roles as negative regulators of gene expression in plants and animals.
A large number of recent papers have described the importance of miRNAs in cancer and a growing body of evidence indicates that many miRNAs are mutated or poorly expressed in tumours. For drug discovery miRNAs are now being investigated as potential biomarkers of prognosis and diagnosis, especially in Oncology but, in the future, this will surely extrapolate to other therapeutic areas.
"The challenge for us as Editors, in what is such an exciting and rapidly expanding field of research, has been what to include and what to miss out since limitations of space have, of necessity, prevented an exhaustive coverage of all possible topics in the field," said one of the editors Philippe Sanseau, PhD. "Nevertheless, our approach has been to include material from some of the very best, most active and upcoming researchers in the field, to provide the reader with a rounded overview of the biology, function and expression of miRNA. To this end, we have grouped the chapters according to the following themes; Basic miRNA Biology, General Characteristics of miRNAs, Species Interest and Function, miRNA Detection Technologies and finally, Bionformatic Approaches to Identification of miRNA and miRNA targets."
This book is a valuable tool for students, university instructors, undergraduate and graduate biology students, and experienced researchers.
The book is available through major academic book distributors, at www.amazon.com, www.dnapress.com, and wherever books are sold. Librarians can use whole sellers such as Ingram or Baker&Taylor or contact IPG http://www.ipgbook.com (a distributor for DNA Press). Orders by telephone from IPG: 800.888.4741
For interviews and review copies contact via e-mail.
BOOK DETAILS:
ISBN: 1933255196
Book binding: Hardcover
Size: 6 x 9 inches
Pages: 200
Price: $65.00
## - #
Press Contact: JAY MORGAN
Company Name: DNA Press
Phone: 267-760-4667
Website: http://www.ipgbook.com/
In accepting AmericanRxStore.com into its prescreened online pharmacy directory, eDrugSearch.com has added the pharmacy's inventory of prescription drugs to the eDrugSearch.com database of 30,000 prescription drug listings.
San Antonio, Texas (PRWEB) May 6, 2007 -- eDrugSearch.com, a free search engine and online community for Americans interested in purchasing safe, low-cost prescription drugs from prescreened Canadian pharmacies and other prescreened international pharmacies, announced that is has accepted AmericanRxStore.com into its pharmacy directory. In accepting AmericanRxStore.com into its directory, eDrugSearch.com has added the pharmacy's inventory of prescription medications into the eDrugSearch.com database.
"Because AmericanRxStore.com is properly licensed and meets eDrugSearch.com's standards of quality and professionalism in online pharmacies, we have accepted its inventory of prescription medications into the eDrugSearch.com database," said Cary Byrd, president of eDrugSearch.com.
With more than 30,000 drug listings, eDrugSearch.com brings together licensed and accredited pharmacies from around the world in one comprehensive, easy-to-use database. The pharmacy page for AmericanRxStore.com is located at: http://www.edrugsearch.com/pharmacies/americanrxstore.html
While many Americans are interested in Canadian pharmacies or other international pharmacies as a means of saving money on their prescriptions, they are often concerned about whether they can trust the quality and safety of the prescription medications they find online. eDrugSearch.com addresses these concerns by only accepting online pharmacies in the eDrugSearch.com database that pass a rigorous prescreening process -- including proof of home-country government licensing and third-party accreditations.
eDrugSearch.com expects to increase online prescription drug listings in the eDrugSearch.com database to 100,000 later this year -- making it easily the most comprehensive resource of its kind.
Additionally, eDrugSearch.com offers up-to-the-minute price search, extensive information on drugs and medical conditions and other features that make it the most advanced destination for online pharmacy consumers. Consumers can register for a free membership with eDrugSearch.com at the following url: http://www.edrugsearch.com/members/register-member.php .
Popular medications available through the eDrugSearch.com database include:
- Accupril
- Actos
- Ambien
- Avandia
- Buspar
- Cephalexin
- Evista
- Lamisil
- Lotensin
- Monopril
- Naproxen
- Prevacid
- Prinivil
- Prozac
- Remeron
- Risperdal
- Zocor
.. along with thousands of other listings.
About eDrugSearch.com
Based in San Antonio, eDrugSearch.com is the Internet destination for those seeking the cost benefits, enhanced privacy and convenience of ordering prescription drugs online from licensed international pharmacies, primarily in Canada. eDrugSearch.com's advanced search features allow members to identify pharmacies with specific licensing requirements and third-party accreditations. eDrugSearch.com is an impassioned advocate for consumers interested in lower drug prices. Visit the company's Web site at www.eDrugSearch.com or the eDrugSearch Blog at www.edrugsearch.com/edsblog .
###
Press Contact: Cary Byrd
Company Name: eDrugSearch.com
Phone: 972-235-3439
Website: http://www.edrugsearch.com
A new design of The Relief Pyramid, the time-tested device for relief of tension headache and underlying stress, is now available online. Designed by an Osteopathic Physician with specialty training in manipulative medicine, The Relief Pyramid targets suboccipital muscle tightness, a frequent cause of common headaches. Effective, portable and inexpensive, it is a promising and powerful tool for millions worldwide who are suffering from chronic headaches.
Tucson, Arizona (PRWEB) May 5, 2007 -- A new design of The Relief Pyramid, the time-tested device for relief of tension headache and underlying stress, is now available online. Designed by an Osteopathic Physician with specialty training in manipulative medicine, The Relief Pyramid targets suboccipital muscle tightness, a frequent cause of common headaches. Effective, portable and inexpensive, it is a promising and powerful tool for millions worldwide who are suffering from chronic headaches.
The most common type of headache is the tension headache. Studies indicate between 63%-93% of men and women over the age of 25 experience tension headache. In today's fast-paced and time-starved world, a common cause of headache is that of stress and tightness/spasm of the suboccipital muscles (found in the upper neck just below the bony skull). While analgesics and different forms of therapy may temporarily alleviate symptoms, headaches often reoccur.
With the availability of The Relief Pyramid headache reducing device, sufferers now have another option -- a drug-free, safe and effective aid that can be used anytime, in the comfort of home or office. Originally, the device was a one-piece monolithic foam product available in two sizes, short and tall. The new and improved Relief Pyramid is now a two-piece adjustable unit, incorporating a reversible top pad. This simple enhancement allows for customization of The Relief Pyramid height to accommodate different patient sizes.
While the latest iteration of the device has only recently been made available, the basic concept behind The Relief Pyramid is not new. Archaeologists have found beds used by the Ancient Egyptians that raised the head during sleep, decompressing the skull (or occiput) from the upper vertebrae of the neck (atlas of the cervical spine